Thio-ccPA is a stabilized analogue of carbacyclic phosphatidic acid (ccPA). It inhibits the lysoPLD activity of Autotaxin (ATX) and acts as an LPA1/3 receptor antagonist. Thio-ccPA decreases the viability of B16F10, A375, and MeWo melanoma cell lines. Addition of endogenous LPA did not reverse these effects in B16F10 cells. Thio-ccPA decreased the number of pulmonary and non-pulmonary metastases in a B16F10 metastatic melanoma mouse model.